CAR-T has transformed cancer treatment, but its One Patient, One Batch model limits scalability. Can allogeneic CAR-T overcome manufacturing scalability bottlenecks and redefine the future of cell therapy?
In the previous articles, I discussed several of the key challenges that have limited the commercialization of CAR-T. The problem has never been its clinical efficacy. The real challenge lies in its One Patient, One Batch manufacturing model.
Each patient requires a completely new manufacturing run using their own T cells, making it extremely difficult to achieve the economies of scale expected in the pharmaceutical industry. Patients typically wait 2–4 weeks for manufacturing to be completed, during which their disease could continue to progress. Manufacturing failures, cryogenic logistics, and the close coordination required between hospitals and GMP manufacturing facilities all add further complexity.
This naturally leads to an important question:
What if CAR-T no longer depended on each patient's own cells? What if it could be manufactured in advance and stored like a conventional medicine, ready for immediate use whenever a patient needs it?
This idea has given rise to one of the most exciting developments in cell therapy today: Allogeneic CAR-T, also known as off-the-shelf CAR-T.
The defining characteristic of autologous CAR-T is that every patient requires an entirely independent manufacturing process.
Unlike monoclonal antibodies or vaccines, where a single production batch can supply thousands of patients, every additional CAR-T patient requires another GMP manufacturing batch.
ShaoChi CHENG
This means:
As a result, the business model of autologous CAR-T resembles a successful neighborhood bakery more than a modern pharmaceutical factory.
When demand increases, the company doesn't simply produce more products in the same facility—it must build up more bakery stores to continuously replicate the entire manufacturing process. Revenue may grow, but the underlying cost structure changes very little, making true economies of scale difficult to achieve.
Before every CAR-T product can be released, it must pass a comprehensive quality control program, including tests for:
Each quality attribute consists of multiple analytical assays, resulting in a substantial amount of testing for every batch.
Since each manufacturing batch serves only one patient, the full cost of quality control must be absorbed by that individual treatment. Unlike traditional pharmaceuticals, these costs cannot be distributed across thousands of doses.
The starting material for CAR-T manufacturing is the patient's own T cells.
However, most CAR-T patients have already undergone multiple rounds of chemotherapy or other intensive treatments, leaving their immune systems significantly weakened.
Their T cells may already be in an exhausted state, with reduced proliferative capacity and a higher risk of manufacturing failure or insufficient product potency.
In other words, every manufacturing run begins with a different starting point.
After leukapheresis, the patient's cells are transported to a GMP facility for genetic engineering, cell expansion, quality testing, and finally shipped back to the treating hospital.
The entire vein-to-vein process typically takes around 2–4 weeks.
For patients with rapidly progressing hematologic cancers, cancer could progress during this waiting period; it becomes a significant clinical risk.
Worse, if manufacturing fails, the patient may ultimately have no CAR-T product available for treatment.
ShaoChi CHENG
Every CAR-T treatment requires close coordination among:
Each patient's treatment resembles a complex project rather than a routine pharmaceutical treatment, increasing operational complexity and costs.
ShaoChi CHENG
To overcome these limitations, researchers began exploring a different approach.
Instead of using each patient's own T cells, what if healthy donor T cells could be used to manufacture large quantities of CAR-T products in advance, frozen, and stored until they are needed?
This is the concept behind allogeneic, or off-the-shelf, CAR-T. Conceptually, it resembles the manufacturing model of conventional pharmaceuticals far more closely than autologous CAR-T.
Compared with autologous CAR-T, allogeneic CAR-T offers several compelling advantages.
A single healthy donor may provide enough cells to manufacture hundreds or even thousands of treatment doses.
This dramatically improves manufacturing efficiency by spreading fixed costs across many patients, significantly reducing the cost of goods sold (COGS).
Because manufacturing is completed before a patient requires therapy, hospitals no longer need to wait weeks for production.
CAR-T products could be administered immediately, much like conventional medicines.
Since all products originate from the same donor source, manufacturing variability is greatly reduced.
Compared with autologous CAR-T, where every patient's cells are biologically different, standardized manufacturing becomes far more achievable.
If this model succeeds, cell therapy could finally evolve from a highly customized medical service into a truly scalable pharmaceutical industry.
However, significant scientific challenges remain.
The biggest obstacle is: The human immune system is remarkably difficult to fool.
Today, the two greatest technical challenges are Graft-versus-Host Disease (GvHD) and Host-versus-Graft (HvG).
Healthy donor T cells still carry their native T-cell receptors (TCRs).
Once infused into a patient, these T cells may recognize the patient's healthy tissues as foreign and attack organs such as the liver, intestines, and skin.
This condition is known as Graft-versus-Host Disease (GvHD). (wikipedia, Graft-versus-Host Disease)
One of today's leading solutions is to eliminate TCR expression by knocking out the TRAC gene using gene-editing technologies such as CRISPR, TALEN, or base editing.
Without TCRs, CAR-T cells rely solely on their engineered CAR to recognize tumor cells while avoiding attacks on normal tissues.
Even if GvHD is eliminated, another challenge remains. The patient's own immune system can still recognize donor-derived CAR-T cells as foreign and rapidly destroy them.
This is known as Host-versus-Graft (HvG). (Learn more about HvG and HLA, Effect of HLA mismatch on acute graft-versus-host disease)
Current strategies include:
The ultimate goal is to help donor-derived CAR-T cells survive longer in the patient's body and maintain sufficient anti-tumor activity.
For the issues mentioned above, several companies are pioneering allogeneic CAR-T development today.
However, it is still in the development stage, and I hope it can achieve great outcomes.
Although allogeneic CAR-T offers tremendous commercial potential, it has not yet demonstrated clinical outcomes that consistently surpass autologous CAR-T.
In oncology, effective treatment will always come before affordable treatment.
For the foreseeable future, autologous CAR-T is likely to remain the dominant treatment approach, while allogeneic CAR-T continues to evolve toward lower costs, broader accessibility, and more scalable manufacturing.
I believe the true value of allogeneic CAR-T is not simply making CAR-T therapy less expensive—it is redefining the business model of cell therapy itself.
Looking back at the history of CAR-T, the first generation proved that engineered immune cells can successfully treat cancer.
The next decade, however, may no longer be defined by who designs the best CAR. Instead, it may belong to those who can build a manufacturing platform capable of large-scale production, lower costs, and reliable global supply.
From a business perspective, the competition in allogeneic CAR-T is ultimately a race to build the best manufacturing platform, not merely the best cell therapy.
I hope that day comes sooner rather than later.
